8-K: Myriad Genetics Settles Shareholder Derivative Lawsuit, Court Approves $950,000 Fee Award

Myriad Genetics has received court approval to settle a shareholder derivative lawsuit, which includes a $950,000 payment for attorneys' fees and the implementation of corporate governance reforms.

Summary

• Myriad Genetics has settled a shareholder derivative lawsuit that was initiated in 2021.
• The settlement, approved by the Court on November 26, 2024, resolves claims of breached fiduciary duties by certain current and former directors and officers.
• As part of the settlement, Myriad Genetics will implement certain corporate governance reforms.
• The company will pay $950,000 for the plaintiffs' attorneys' fees and expenses.
• The settlement includes no admission of liability or wrongdoing by any party.
• The court has dismissed the consolidated derivative action with prejudice.

Sentiment

Score: 6

Explanation: The settlement resolves a legal issue, which is positive, but the cost of the settlement and the underlying allegations are negative. Overall, the sentiment is neutral to slightly positive.

Positives

• The settlement resolves a long-standing legal issue for Myriad Genetics.
• The company avoids further litigation costs and uncertainty.
• The implementation of corporate governance reforms could improve the company's operations and reputation.
• The settlement was approved by the court, providing a clear resolution.

Negatives

• Myriad Genetics will incur a $950,000 expense for attorneys' fees and expenses.
• The lawsuit suggests potential past issues with fiduciary duties of directors and officers.

Risks

• The settlement does not fully eliminate the risk of future litigation.
• The implementation of corporate governance reforms may require additional resources and effort.
• The underlying issues that led to the lawsuit could potentially resurface in the future.

Future Outlook

The company will implement corporate governance reforms as part of the settlement agreement.

Industry Context

Shareholder derivative lawsuits are not uncommon, particularly when there are allegations of breaches of fiduciary duty. This settlement is a step towards resolving these issues for Myriad Genetics and is similar to other companies that have faced similar litigation.

Comparison to Industry Standards

• Many public companies face shareholder derivative lawsuits, often related to corporate governance or fiduciary duty issues.
• The settlement amount of $950,000 for attorneys' fees is within the typical range for such cases, although the specific amount varies based on the complexity and duration of the litigation.
• The requirement to implement corporate governance reforms is a common outcome in these types of settlements, aiming to prevent future issues.
• Companies like Teva Pharmaceuticals and Wells Fargo have faced similar derivative lawsuits, resulting in settlements that included both monetary payments and governance changes.

Corporate Governance

Legal Proceedings

• The shareholder derivative lawsuit against Myriad Genetics has been settled.
• The consolidated Derivative Action was dismissed with prejudice.

Stakeholder Impact

• Shareholders benefit from the resolution of the lawsuit and the implementation of corporate governance reforms.
• The company incurs a one-time expense of $950,000 for attorneys' fees.
• Employees may see changes in corporate governance practices.

Next Steps

• Myriad Genetics will implement the agreed-upon corporate governance reforms.
• The federal derivative plaintiff, Marcey, will file the Court's settlement approval and dismissal order in the Federal Derivative Action and seek prompt dismissal with prejudice of that Federal Derivative Action.

Key Dates

Keywords

shareholder derivative lawsuit, settlement, corporate governance, litigation, attorneys' fees, fiduciary duty, Myriad Genetics